Novartis’ canakinumab falls short in phase 3 lung cancer trialNovartis’ attempt to treat cancer with the anti-inflammatory drug canakinumab was always a long shot, but it’s nevertheless Share XNovartis’ canakinumab falls short in phase 3 lung cancer trialhttps://pharmaphorum.com/news/novartis-canakinumab-falls-short-in-phase-3-lung-cancer-trial/
